GEN Podcasts

Genetic Engineering & Biotechnology News (GEN)
  • 0.0（0）
  • 生命科学

Genetic Engineering & Biotechnology News (GEN) has retained its position as the premier biotech publication since its launch in 1981. GEN publishes a print edition monthly and has additional exclusive editorial content online, including news and analysis as well as webinars, videos, and polls. GEN's unique news and technology focus covers the entire bioproduct life cycle, including drug discovery, early-stage R&D, applied research (e.g., omics, biomarkers, and diagnostics), bioprocessing, and commercialization. GEN's print magazine, which also can easily be accessed online, includes feature articles on emerging technologies, product roundups, in-depth overviews from key scientific and bioindustry meetings, and industry-standard tutorials and technical articles on drug discovery, bioprocessing, and assay technologies. Hosted on Acast. See acast.com/privacy for more information.

エピソード

  1. 7月27日

    Beyond the Technology: AI Readiness in Regulated Laboratories

    This episode establishes the broader context for AI adoption. Rather than focusing on AI tools themselves, the discussion explores what laboratories must have in place before AI can be applied responsibly.  Key discussion areas include:  Why fragmented workflows and disconnected systems limit AI effectiveness The importance of trusted, connected laboratory data Human-guided AI and human-in-the-loop governance Why compliance and auditability should be built into AI-enabled workflows from the outset Relevant reference to LabVantage CORTEX:  LabVantage CORTEX embeds AI within laboratory execution workflows so that intelligence operates within existing scientific and compliance processes, rather than as an external layer. Hosted on Acast. See acast.com/privacy for more information.

  2. 4月21日

    Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical Readiness.

    Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a number of manufacturing challenges, including higher doses, tighter control of impurities, greater batch consistency, and scalable processes to meet both clinical and commercial needs. In this GEN Podcast, two experts from SK Pharmteco, a global CMO, address these challenges and lay out some best practices that guide the manufacture of lentiviral vectors with the requisite purity, robustness, and economic feasibility required for widespread clinical adoption. Guest speakers: Mardhani Aparajithan, Director of Manufacturing, Science and Technology, SK Pharmteco Tatiana Nanda, PhD, CTO, Cell and Gene Therapy, SK Pharmteco Moderator: Kevin Davies, PhD, Editorial Director, GEN Hosted on Acast. See acast.com/privacy for more information.

  3. 2025/04/11

    The Future of Bioinformatics: Scaling Interactive and Computational Workflows with Seqera

    Sponsored by Seqera As data volumes in life sciences continue to grow, bioinformaticians and researchers are more dependent than ever on solutions that help them streamline workflows, manage data, and scale their research. In this timely podcast, Evan Floden, CEO and co-founder of Seqera, shares how his company is addressing these needs through Nextflow—the open-source orchestrator for scalable, reproducible, and portable scientific workflows—and Seqera Platform, a unified solution for the entire scientific data lifecycle. He also discusses how Seqera has become a widely adopted solution, trusted by 13 of the top 20 pharmaceutical companies, empowering breakthroughs in drug discovery, genomics, clinical research, and.beyond. Hosted on Acast. See acast.com/privacy for more information.

  4. 2025/04/08

    Smart Vector Design for Improved Cell and Gene Therapies

    In the episode, we’re talking about vector design and delivery for gene therapies. The field of cell and gene therapies is advancing, but there are still challenges with delivery vectors that need to be addressed. In this podcast, experts discuss current immunogenicity hurdles, evolving DMPK strategies, and a new generation of bioanalytical tools that are contributing to the progress in the field. Hosted on Acast. See acast.com/privacy for more information.

  5. 2025/04/08

    From Functional Genomics to Cell Therapy: The Role of CRISPR-based Gene Editing

    There are an estimated 6,000 Mendelian diseases, most of which still lack cures. Gene editing is an essential technology for studies aimed at generating data about disease-causing gene mutations and networks in order to identify optimal therapeutic targets. In this episode, experts will discuss applications of gene editing to improve scientists understanding of the relationship between variant and disease in functional genomics studies. They will also talk about the Dharmacon product suite which is designed for CRISPR-based targeted editing in a wide range of cells. Hosted on Acast. See acast.com/privacy for more information.

  6. 2025/03/28

    Precision Base Editing Meets Single-Cell Multiomics to Advance Cell and Gene Therapies

    In this episode, you’ll hear a group of experts discussing base editing and how the technology is helping scientists engineer powerful cell therapies for various diseases including novel CAR-T therapies and hypoimmunogenic induced pluripotent stem cells. During the discussion, they will cover the merits of the Pin-point base editing platform, which introduces gene modifications without relying on double-strand DNA breaks, as well as how TotalSeq reagents, which confirm the safety and efficiency of editing with the Pin-point platform, support single cell multiomics analysis of edited cells. Hosted on Acast. See acast.com/privacy for more information.

  7. 2024/01/22

    Cas-CLOVER: An advanced gene editing technology capable of meeting crop improvement challenges

    This GENcast is the final installment in a 3-part series on Cas-CLOVER, “the proven alternative to CRISPR/Cas9,” sponsored by Demeetra AgBio. Demeetra has built extensive gene editing know-how, complementing its internally developed as well as globally sourced portfolio of intellectual property, which it transfers to its partners through simple commercial licenses with freedom to operate. Jack Crawford, CEO of Demeetra, sat down with Dr. Leena Tripathi, Director of the Eastern Africa Hub and Leader of the Biotechnology Program at the International Institute of Tropical Agriculture (IITA), and David Norman, Senior Scientist in the Plant Systems Group at Demeetra. They discuss how combining advanced gene editing techniques with traditional methods for plant breeding can meet the global challenges of feeding a rapidly growing population. Additionally, they discuss their brief communication in Plant Biotechnology Journal that was published in 2023 demonstrating Cas-CLOVER as an alternative genome-editing tool to CRISPR/Cas9 by targeting MusaPDS in the banana genome. Hosted on Acast. See acast.com/privacy for more information.

  8. 2023/12/14

    The Possibilities of Cas-CLOVER and piggyBac

    This GENcast is part 2 of a 3-part series on Cas-CLOVER, “the proven alternative to CRISPR/Cas9,” sponsored by Demeetra AgBio. Demeetra has built extensive gene editing know-how, complementing its internally developed as well as globally sourced portfolio of intellectual property, which it transfers to its partners through simple commercial licenses with freedom to operate. Jack Crawford, CEO of Demeetra, sat down with Dr. Molly Duman Scheel, professor in the department of medical and molecular genetics at the Indiana University School of Medicine - South Bend, and Dr. Corey Brizzee, director of gene editing at Demeetra. The discussion focuses on the use of advanced gene editing technologies to create scalable, and eco-friendly biopesticides as described in the panelists’ latest publications in Journal of Fungi’s special issue “Development and Utilization of Yeast Resources” and Fermentation’s special issue “Advances in Yeast Biotechnology from Genomics to Industry.” Panelists “Two of the primary obstacles to using RNAi pesticides is the steep cost of production. How are you going to get it into the field, and how is it going to be stable, [gene edited] yeast solve both of these issues for us”—Dr. Molly Duman Scheel “We wanted to make the expression as high as we could…we created a biomanufacturing platform [in yeast] with Cas-CLOVER by editing nutritional markers…this allowed for easy selection when we combined [the platform] with piggyBac to deliver the biopesticide RNAi”—Dr. Corey Brizzee Hosted on Acast. See acast.com/privacy for more information.

  9. 2023/12/14

    Addressing Barriers in Gene Therapy

    In this podcast episode, join us as we delve into addressing regulatory challenges in gene therapy with María Orío, the Head of Regulatory Affairs at Viralgen. Learn about the mission of Viralgen as a Contract Development and Manufacturing Organization specializing in Adeno-Associated Virus (AAV) gene therapy products. Uncover the unique challenges faced by the gene therapy industry, from the evolving regulatory landscape to the setting of acceptance criteria with limited available data. Learn how Viralgen addresses these challenges, leveraging historical data and innovative approaches. Gain valuable insights from the Chemistry, Manufacturing, and Controls (CMC) perspective, while learning how regulatory agencies are actively supporting sponsors in their quest for life-changing treatments. Hosted on Acast. See acast.com/privacy for more information.

  • 9話のエピソード

番組について

Genetic Engineering & Biotechnology News (GEN) has retained its position as the premier biotech publication since its launch in 1981. GEN publishes a print edition monthly and has additional exclusive editorial content online, including news and analysis as well as webinars, videos, and polls. GEN's unique news and technology focus covers the entire bioproduct life cycle, including drug discovery, early-stage R&D, applied research (e.g., omics, biomarkers, and diagnostics), bioprocessing, and commercialization. GEN's print magazine, which also can easily be accessed online, includes feature articles on emerging technologies, product roundups, in-depth overviews from key scientific and bioindustry meetings, and industry-standard tutorials and technical articles on drug discovery, bioprocessing, and assay technologies. Hosted on Acast. See acast.com/privacy for more information.

情報

  • クリエイター
    Genetic Engineering & Biotechnology News (GEN)
  • 配信期間
    26年
  • エピソード
    9
  • 制限指定
    不適切な内容を含まない
  • Copyright
    © Genetic Engineering & Biotechnology News (GEN)
  • 番組のWebサイト
    GEN Podcasts